Volume | 8,496,171 |
|
|||||
News | - | ||||||
Day High | 10.50 | Low High |
|||||
Day Low | 8.84 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Altimmune Inc | ALT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
9.06 | 8.84 | 10.50 | 10.18 | 8.89 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
41,273 | 8,496,171 | US$ 10.02 | US$ 85,146,017 | - | 2.09 - 14.84 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:47 | formt | 600 | US$ 10.32 | USD |
Altimmune (ALT) Options Flow Summary
Altimmune Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
546.42M | 53.73M | - | -68k | -84.71M | -1.58 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Altimmune News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.40 | 10.50 | 7.92 | 8.86 | 4,158,419 | 0.92 | 9.79% |
1 Month | 13.59 | 14.05 | 7.92 | 10.15 | 4,687,895 | -3.27 | -24.06% |
3 Months | 9.925 | 14.84 | 7.92 | 10.58 | 5,895,810 | 0.395 | 3.98% |
6 Months | 2.50 | 14.84 | 2.09 | 7.79 | 7,444,982 | 7.82 | 312.80% |
1 Year | 4.81 | 14.84 | 2.09 | 7.10 | 4,540,412 | 5.51 | 114.55% |
3 Years | 13.75 | 23.49 | 2.09 | 8.96 | 2,488,315 | -3.43 | -24.95% |
5 Years | 2.95 | 35.10 | 1.45 | 10.14 | 2,103,244 | 7.37 | 249.83% |
Altimmune Description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). |